The approval of Yeztugo is a momentous step in improving PrEP options available for people vulnerable to contracting ...

Last week the US Food and Drug Administration approved Gilead Sciences Yeztugo (lenacapavir) for the prevention of HIV ...

World leaders are dismantling global health programs and cutting back foreign aid. Will an extraordinary new medicine be able ...

HIV-1 negative study participants (median age, 21 years; 99.9% Black) were randomly assigned 2:2:1 to receive twice-yearly subcutaneous lenacapavir (n=2134), once daily Descovy (emtricitabine and ...

Patients with HIV receiving 3-drug ART with BIC/FTC/TAF exhibited low rates of viremia, particularly those with high treatment adherence.

A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...

The effect of tenofovir amibufenamide (TMF) on blood lipid profiles in patients with chronic hepatitis B (CHB) remains unclear. This study aimed to explore whether TMF affects blood lipids during ...

About The Study: In this study of people taking pre-exposure prophylaxis (PrEP) for HIV, tenofovir alafenamide fumarate (TAF) use was found to be associated with higher incident hypertension and ...

Li M, Yao L, Qin Y, Li Y, Lu M, Ma M, Yang M, Guo K, Wang Q, Zhang Z, Zhu L, Li X, Yang K. Tenofovir versus entecavir for children and adults with chronic hepatitis B (Protocol). Cochrane Database of ...

Although emtricitabine/tenofovir isn’t typically associated with erectile dysfunction, ED is more common in men living with HIV due to added psychological and physical pressures, such as a new ...